does semaglutide cause kidney damage FLOW clinical Trial (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes and chronic kidney disease compared to placebo. Investigators FLOWing with the SemagluTIDE —

To get a more specific cost feel free to book a consultation

Foundayo (Orforglipron) Foundayo, approved in April 2026, provides the latest advancements in GLP-1 weight management

Berriesincluding blueberries, raspberries, and strawberriesoffer high fiber, low sugar profiles that complement GLP-1 therapy's appetite-suppressing effects without metabolic interference

The findings will pave the way for semaglutide and similar drugs to become frontline treatments for this chronic condition

These underlying metabolic differences in lipedema adipose tissuealtered lipid metabolism, microvascular changes, and fibrotic remodelingcause poor fat loss results

We conducted additional analyses using an as-treated definition for drug use, in which patients were censored at treatment discontinuation or switch to the other study drug